[1]. Bray, F., et al., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018. 68(6): p. 394-424.
[2]. Siegel, R.L., K.D. Miller and A. Jemal, Cancer statistics, 2019. CA Cancer J Clin, 2019. 69(1): p. 7-34.
[3]. Torre, L.A., et al., Global cancer statistics, 2012. CA Cancer J Clin, 2015. 65(2): p. 87-108.
[4]. Torre, L.A., R.L. Siegel and A. Jemal, Lung Cancer Statistics. Adv Exp Med Biol, 2016. 893: p. 1-19.
[5]. Goldstraw, P., et al., Non-small-cell lung cancer. Lancet, 2011. 378(9804): p. 1727-40.
[6]. Travis, W.D., Pathology of lung cancer. Clin Chest Med, 2011. 32(4): p. 669-92.
[7]. I, H. and J.Y. Cho, Lung Cancer Biomarkers. Adv Clin Chem, 2015. 72: p. 107-70.
[8]. Pellegrini, F. and D.R. Budman, Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest, 2005. 23(3): p. 264-73.
[9]. Correia, J.J. and L. Wilson, Microtubules and microtubule-associated proteins. Preface. Methods Cell Biol, 2013. 115: p. xix-xx.
[10]. Goodson, H.V. and E.M. Jonasson, Microtubules and Microtubule-Associated Proteins. Cold Spring Harb Perspect Biol, 2018. 10(6).
[11]. Tovey, C.A. and P.T. Conduit, Microtubule nucleation by gamma-tubulin complexes and beyond. Essays Biochem, 2018. 62(6): p. 765-780.
[12]. Rodrigues-Ferreira, S., A. Molina and C. Nahmias, Microtubule-associated tumor suppressors as prognostic biomarkers in breast cancer. Breast Cancer Res Treat, 2020. 179(2): p. 267-273.
[13]. Nayak, L., et al., Multicenter phase 2 study of patupilone for recurrent or progressive brain metastases from non-small cell lung cancer. Cancer, 2015. 121(23): p. 4165-72.
[14]. Ferrara, R., et al., Tubulin inhibitors in non-small cell lung cancer: looking back and forward. Expert Opin Pharmacother, 2016. 17(8): p. 1113-29.
[15]. Tagliamento, M., et al., Microtubule-targeting agents in the treatment of non-small cell lung cancer: insights on new combination strategies and investigational compounds. Expert Opin Investig Drugs, 2019. 28(6): p. 513-523.
[16]. Cheng, C.C., et al., Cell Pleomorphism and Cytoskeleton Disorganization in Human Liver Cancer. In Vivo, 2016. 30(5): p. 549-55.
[17]. Huang, M., et al., FAM83D, a microtubule-associated protein, promotes tumor growth and progression of human gastric cancer. Oncotarget, 2017. 8(43): p. 74479-74493.
[18]. Overby, A., et al., Naturally occurring phenethyl isothiocyanate-induced inhibition of gastric cancer cell growth by disruption of microtubules. J Gastroenterol Hepatol, 2014. 29 Suppl 4: p. 99-106.
[19]. Cetti, E., et al., Mitosis perturbation by MASTL depletion impairs the viability of thyroid tumor cells. Cancer Lett, 2019. 442: p. 362-372.
[20]. Jordan, M.A. and L. Wilson, Microtubules as a target for anticancer drugs. Nat Rev Cancer, 2004. 4(4): p. 253-65.
[21]. Yang, H., A. Ganguly and F. Cabral, Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs. J Biol Chem, 2010. 285(42): p. 32242-50.
[22]. Hutchins, J.R.A., et al., Systematic Analysis of Human Protein Complexes Identifies Chromosome Segregation Proteins. Science, 2010. 328(5978): p. 593-599.
[23]. Jiang, P., S. Zheng and L. Lu, Mitotic-Spindle Organizing Protein MztA Mediates Septation Signaling by Suppressing the Regulatory Subunit of Protein Phosphatase 2A-ParA in Aspergillus nidulans. Front Microbiol, 2018. 9: p. 988.
[24]. Teixido-Travesa, N., et al., The gammaTuRC revisited: a comparative analysis of interphase and mitotic human gammaTuRC redefines the set of core components and identifies the novel subunit GCP8. Mol Biol Cell, 2010. 21(22): p. 3963-72.
[25]. Goldstraw, P., et al., The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol, 2016. 11(1): p. 39-51.
[26]. Garcin, C. and A. Straube, Microtubules in cell migration. Essays Biochem, 2019. 63(5): p. 509-520.
[27]. Liu, P., Y.K. Choi and R.Z. Qi, NME7 is a functional component of the gamma-tubulin ring complex. Mol Biol Cell, 2014. 25(13): p. 2017-25.
[28]. Ersahin, T., N. Tuncbag and R. Cetin-Atalay, The PI3K/AKT/mTOR interactive pathway. Mol Biosyst, 2015. 11(7): p. 1946-54.
[29]. Liu, L., Y. Wang and Q. Yu, The PI3K/Akt signaling pathway exerts effects on the implantation of mouse embryos by regulating the expression of RhoA. Int J Mol Med, 2014. 33(5): p. 1089-96.
[30]. Porta, C., C. Paglino and A. Mosca, Targeting PI3K/Akt/mTOR Signaling in Cancer. Front Oncol, 2014. 4: p. 64.
[31]. Chen, J., et al., Akt1 regulates pathological angiogenesis, vascular maturation and permeability in vivo. Nat Med, 2005. 11(11): p. 1188-96.
[32]. Kandel, E.S., et al., Activation of Akt/protein kinase B overcomes a G(2)/m cell cycle checkpoint induced by DNA damage. Mol Cell Biol, 2002. 22(22): p. 7831-41.
[33]. Song, G., G. Ouyang and S. Bao, The activation of Akt/PKB signaling pathway and cell survival. J Cell Mol Med, 2005. 9(1): p. 59-71.
[34]. Sardiello, M., et al., A gene network regulating lysosomal biogenesis and function. Science, 2009. 325(5939): p. 473-7.
[35]. Somanath, P.R., et al., Akt1 in endothelial cell and angiogenesis. Cell Cycle, 2006. 5(5): p. 512-8.
[36]. Auguste, A., et al., Molecular analyses of juvenile granulosa cell tumors bearing AKT1 mutations provide insights into tumor biology and therapeutic leads. Hum Mol Genet, 2015. 24(23): p. 6687-98.
[37]. Sykes, S.M., et al., AKT/FOXO signaling enforces reversible differentiation blockade in myeloid leukemias. Cell, 2011. 146(5): p. 697-708.
[38]. Liao, S.Y., et al., AKT-mediated phosphorylation enhances protein stability and transcription activity of ZNF322A to promote lung cancer progression. Oncogene, 2019. 38(41): p. 6723-6736.
[39]. Revathidevi, S. and A.K. Munirajan, Akt in cancer: Mediator and more. Semin Cancer Biol, 2019. 59: p. 80-91.
[40]. Fogeron, M., et al., LGALS3BP regulates centriole biogenesis and centrosome hypertrophy in cancer cells. Nature communications, 2013. 4(1): p. 1531.
[41]. Stampolidis, P., A. Ullrich and S. Iacobelli, LGALS3BP, lectin galactoside-binding soluble 3 binding protein, promotes oncogenic cellular events impeded by antibody intervention. Oncogene, 2015. 34(1): p. 39-52.
[42]. Zhang, X., et al., Increased LGALS3BP promotes proliferation and migration of oral squamous cell carcinoma via PI3K/AKT pathway. Cellular Signalling, 2019. 63: p. 109359.
[43]. Oka, N., et al., Galectin-3 Inhibits Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand–Induced Apoptosis by Activating Akt in Human Bladder Carcinoma Cells. Cancer Research, 2005. 65(17): p. 7546-7553.